This document discusses quality control testing for parenteral products. There are three phases of testing: 1) raw material testing, 2) production material testing before filling, and 3) finished product testing. Raw material testing includes tests for purity, conductivity, solid content, stability, and pyrogens using rabbit tests or LAL tests. Production material testing checks volume, strength, pH, turbidity, and color and includes pyrogen testing and sterility testing. Finished product testing focuses on sterility, pyrogens, clarity, leaks, and assay. Proper quality control testing at all stages of production is important to ensure parenteral products meet standards for sterility, isotonicity, and particle freedom.
Quality Control Tests Of Capsules dosage form.
1. Weight Variation Test
2. Content Uniformity Test
3. Dissolution Test
4. Disintegration Test
5. Leak Test
Quality Control Tests Of Capsules dosage form.
1. Weight Variation Test
2. Content Uniformity Test
3. Dissolution Test
4. Disintegration Test
5. Leak Test
University Institute of Pharmaceutical Sciences is a flag bearer of excellence in Pharmaceutical education and research in the country. Here is another initiative to make study material available to everyone worldwide. Based on the new PCI guidelines and syllabus here we have a presentation dealing with the types of parenteral formulation including the types of parenteral route for administration along withcomponents of parenteral formulation.
Thank you for reading.
Hope it was of help to you.
UIPS,PU team
IPQC Tests for capsules As per IP, BP & USPPramod Ramane
IPQC- In Process Quality Control Tests for Capsules are
1. Uniformity Of Content
2. Disintigration Test
3. Weight Variation Test
4. Dissolution Test
The tests are with Acceptance limits/Criteria as per Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) & United States Pharmacopoeia (USP)
In Process Quality Control Tests (IPQC) for Solid Dosage FromSagar Savale
IPQC is concerned with providing accurate, specific, & definite descriptions of the procedures to be employed, from, the receipt of raw materials to the release of the finished dosage forms.
Parenterals are the sterile preparation that is directly administered into the circulatory system avoiding the enteral route. And these preparation provide rapid onset of action that is why the administered preparation must be safe.
Stability problem arise from microbial contamination of these products so sterility and stability must be ensured for these preparations.
To ensure their sterility and stability, regulations regarding to quality control through pharmacopeial specifications has great importance.
University Institute of Pharmaceutical Sciences is a flag bearer of excellence in Pharmaceutical education and research in the country. Here is another initiative to make study material available to everyone worldwide. Based on the new PCI guidelines and syllabus here we have a presentation dealing with the types of parenteral formulation including the types of parenteral route for administration along withcomponents of parenteral formulation.
Thank you for reading.
Hope it was of help to you.
UIPS,PU team
IPQC Tests for capsules As per IP, BP & USPPramod Ramane
IPQC- In Process Quality Control Tests for Capsules are
1. Uniformity Of Content
2. Disintigration Test
3. Weight Variation Test
4. Dissolution Test
The tests are with Acceptance limits/Criteria as per Indian Pharmacopoeia (IP), British Pharmacopoeia (BP) & United States Pharmacopoeia (USP)
In Process Quality Control Tests (IPQC) for Solid Dosage FromSagar Savale
IPQC is concerned with providing accurate, specific, & definite descriptions of the procedures to be employed, from, the receipt of raw materials to the release of the finished dosage forms.
Parenterals are the sterile preparation that is directly administered into the circulatory system avoiding the enteral route. And these preparation provide rapid onset of action that is why the administered preparation must be safe.
Stability problem arise from microbial contamination of these products so sterility and stability must be ensured for these preparations.
To ensure their sterility and stability, regulations regarding to quality control through pharmacopeial specifications has great importance.
To avoid contamination, the aseptic technique is the method of reducing or removing contaminants from entering the operative field in surgery or medicine.
University Institute of Pharmaceutical Sciences is a flag bearer of excellence in Pharmaceutical education and research in the country. Here is another initiative to make study material available to everyone worldwide. Based on the new PCI guidelines and syllabus here we have a presentation dealing with the quality control tests of parenteral as referred in the pharmacopoeia.
Thank you for reading. Hope it was of help to you.
UIPS,PU team
In Process Quality Control Tests (IPQC) For Parenteral or Sterile Dosage FormsSagar Savale
These are the tests performed between QA and QC and provides for the authorization of approved raw materials for manufacturing based on actual laboratory testing generally called as IPQC such as physical, chemical, microbiologic and biologic tests.
Read| The latest issue of The Challenger is here! We are thrilled to announce that our school paper has qualified for the NATIONAL SCHOOLS PRESS CONFERENCE (NSPC) 2024. Thank you for your unwavering support and trust. Dive into the stories that made us stand out!
A Strategic Approach: GenAI in EducationPeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Welcome to TechSoup New Member Orientation and Q&A (May 2024).pdfTechSoup
In this webinar you will learn how your organization can access TechSoup's wide variety of product discount and donation programs. From hardware to software, we'll give you a tour of the tools available to help your nonprofit with productivity, collaboration, financial management, donor tracking, security, and more.
Embracing GenAI - A Strategic ImperativePeter Windle
Artificial Intelligence (AI) technologies such as Generative AI, Image Generators and Large Language Models have had a dramatic impact on teaching, learning and assessment over the past 18 months. The most immediate threat AI posed was to Academic Integrity with Higher Education Institutes (HEIs) focusing their efforts on combating the use of GenAI in assessment. Guidelines were developed for staff and students, policies put in place too. Innovative educators have forged paths in the use of Generative AI for teaching, learning and assessments leading to pockets of transformation springing up across HEIs, often with little or no top-down guidance, support or direction.
This Gasta posits a strategic approach to integrating AI into HEIs to prepare staff, students and the curriculum for an evolving world and workplace. We will highlight the advantages of working with these technologies beyond the realm of teaching, learning and assessment by considering prompt engineering skills, industry impact, curriculum changes, and the need for staff upskilling. In contrast, not engaging strategically with Generative AI poses risks, including falling behind peers, missed opportunities and failing to ensure our graduates remain employable. The rapid evolution of AI technologies necessitates a proactive and strategic approach if we are to remain relevant.
Palestine last event orientationfvgnh .pptxRaedMohamed3
An EFL lesson about the current events in Palestine. It is intended to be for intermediate students who wish to increase their listening skills through a short lesson in power point.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
The French Revolution, which began in 1789, was a period of radical social and political upheaval in France. It marked the decline of absolute monarchies, the rise of secular and democratic republics, and the eventual rise of Napoleon Bonaparte. This revolutionary period is crucial in understanding the transition from feudalism to modernity in Europe.
For more information, visit-www.vavaclasses.com
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
2024.06.01 Introducing a competency framework for languag learning materials ...Sandy Millin
http://sandymillin.wordpress.com/iateflwebinar2024
Published classroom materials form the basis of syllabuses, drive teacher professional development, and have a potentially huge influence on learners, teachers and education systems. All teachers also create their own materials, whether a few sentences on a blackboard, a highly-structured fully-realised online course, or anything in between. Despite this, the knowledge and skills needed to create effective language learning materials are rarely part of teacher training, and are mostly learnt by trial and error.
Knowledge and skills frameworks, generally called competency frameworks, for ELT teachers, trainers and managers have existed for a few years now. However, until I created one for my MA dissertation, there wasn’t one drawing together what we need to know and do to be able to effectively produce language learning materials.
This webinar will introduce you to my framework, highlighting the key competencies I identified from my research. It will also show how anybody involved in language teaching (any language, not just English!), teacher training, managing schools or developing language learning materials can benefit from using the framework.
2. • Quality Control of Parenteral Products
• Mandatory quality of injection
1. Sterile
2. Isotonic
3. Free from foreign particles
• These significant qualities are ensured by
employing a set of specific tests
• Such tests are performed throughout the
production operation.
3. • Quality Control of Parenteral Products
• There are 3 phases for employing tests:
1. Raw material testing
2. Production material testing (intermediate
products) before filling
3. Finished product testing
4. • Quality Control of Parenteral Products
1. Raw material testing
Test for purity
Conductivity
testSolid content
test
Stability testing
Pyrogen tests
Rabbit test
LAL test
5. • Quality Control of Parenteral Products
2. Production material testing
Volume check
Strength
pH
Turbidity
Color
Pyrogen test
Sterility (direct inoculation &
indirect method )
6. • Quality Control of Parenteral Products
3. Finished product testing
Sterility test
Pyrogen test
Clarity test
Leak test
Assay
7. • Quality Control of Parenteral Products
1. Raw material testing:
I. Test for purity: purity of API is checked with
the aid of assay as per monograph
II. Conductivity test: Conductivity is measured
by conductometer.
• It measures the conductivity of vehicle used in
sterile preparation.
8. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test:
• Fever producing, metabolic by-products of
microbial growth and death.
• Bacterial Pyrogens are called “Endotoxins”.
• Gram negative bacteria produce more potent
endotoxins than gram + bacteria and fungi.
9. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test (Rabbit test):
• Test is conducted using rabbit as a test
animal.
• healthy adult rabbits of either sex, each
weighing 1.5 kg are selected
• Do not use any rabbit
• having a temp higher than 39.8 ℃
10. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test (Rabbit test):
• The volume of injection is NLT 0.5ml/kg &
NMT 10ml/kg of body weight
• Temperature is recorded by inserting the
thermometer in rectum of rabbit to depth of
about 5 cm
11. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test (Rabbit test):
• Inject the solution under examination slowly
into the marginal veins of the ear of each
rabbit over a period not exceeding 4 mins.
• Record the temperature of each animal at half
hourly intervals for 3 hours after injection.
12. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test (Rabbit test):
• The difference between the initial temperature
and
• the maximum temperature which is the
highest
• temperature recorded for a rabbit is taken to
be its response.
13. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test (Rabbit test):
No. of Rabbits
Individual Temperature rise
(°c)
Temperature rise
in groups (°c) Test
3 0.6 1.4 Pass
If above not
passes
3+5 =8 rabbits
0.6 3.7 pass
14. • Quality Control of Parenteral Products
1. Raw material testing:
III. Pyrogen test: Limulus amebocyte lysate
(LAL)
• To detect or quantify endotoxins of gram-ve
bacterial origin
• Reagent: amoebocyte lysate enzyme from
horseshoe crab
15. • Quality Control of Parenteral Products
III. Pyrogen test: Limulus amebocyte lysate
(LAL)
• The test is based on the gelling properties of
enzyme extracted from the horseshoe crab of
Limulus polyphemus.
• enzymes when come in contact with solution
containing bacterial endotoxin
• Produces turbidity, precipitation or gelation of
the mixture.
16. • Quality Control of Parenteral Products
III. Pyrogen test: Limulus amebocyte lysate
(LAL)
• Degree of Gelling related to amount of
Endotoxin present.
• Procedure:
• equal Volume of LAL reagent and test solution
(usually 0.1 ml of each) are mixed in a de-
pyrogenated test-tube
• Incubation at 37°C, 1 hour remove the tube - invert
at (180°) observe the result
17. • Quality Control of Parenteral Products
III. Pyrogen test: Limulus amebocyte lysate
(LAL)
• Quantitative estimation is done with the help
of spectrophotometer.
• Advantages
• Fast - 60 minutes vs. 180 minutes
• Greater Sensitivity ,Less Variability
• Much Less False, Positives ,Much Less
Expensive
18. • Quality Control of Parenteral Products
III. Pyrogen test: Limulus amebocyte lysate
(LAL)
• Advantages
• Alternative to Animal Model, cheaper,
• Particularly useful for:
• Radiopharmaceuticals and cytotoxic agents
• Blood products
• Water for injection
19. • Quality Control of Parenteral Products
2. Production material testing (before filling)
I. Volume check: final volume of the container
is checked to ensure the uniformity of final
volume Labelled Size Mobile Liquid (ml) Viscous Liquid
(ml)
0.5 ml 0.1 0.12
1 ml 0.1 0.15
2 ml 0.15 0.25
5 ml 0.3 0.5
20. • Quality Control of Parenteral Products
2. Production material testing (before filling)
II. pH: it should be maintained as per the
standard parameter.
• Two different types of methods used in
measurement of pH.
A. Dip a piece of pH paper into the sample.
B. pH meter
21. • Quality Control of Parenteral Products
3. Finished product testing:
I. Sterility test:
• It is a procedure carried out to detect and
• conform absence of any viable form of
microbes in pharmacopoeial preparation or
product.
• PRINCIPLE : If the microorganism are present
in the product can be indicated by a turbidity in
the clear medium.
22. • Quality Control of Parenteral Products
3. Finished product testing:
I. Sterility test:
• Sterility test is destructive test thus it is
impossible to test every item for sterility.
• That’s why, a fixed percentage of the final
container are selected
• According to Indian Pharmacopoeia
23. • Quality Control of Parenteral Products
3. Finished product testing:
I. Sterility test:
Number of items in the batch Minimum number of items to be tested
for each medium
Not more than 100 containers 10 per cent or 4 containers
More than 100 but not more than 500 10 containers
More than 500 containers . 2 per cent or 20 containers (10
containers for large-volume
parenterals) whichever is the less
24. • Quality Control of Parenteral Products
3. Finished product testing:
I. Sterility test:
Media to be used in the
sterility test
Fluid Thioglycollate Medium
(FTM)
Soyabean-casein Digest
Medium
(SCDM)
Methods
Method - A
Membrane filtration method
Method- B
Direct inoculation method
25. • Quality Control of Parenteral Products
I. Sterility test:
• Method – A (Membrane Filtration Test)
• A membrane has a nominal pore size not greater
than 0.45μ and diameter of approximately 50mm.
• This method basically involves filtration of Sample
through membrane filters.
• The filtration is assisted under Vacuum
• after filtration completion the membrane is cut into 2
halves
26. • Quality Control of Parenteral Products
I. Sterility test:
• Method – A (Membrane Filtration Test)
• one halve is placed in a test tube containing FTM
medium
• Second halve is dipped into another test tube
containing SCDM medium
• Incubate the media for not less than 14 days.
• All steps of this procedure are performed aseptically
in a Laminar Flow Hood
27. • Quality Control of Parenteral Products
• Membrane is washed
Thrice with 100 ml sterile water
Prior to test.
• Fatty formulations can be
Diluted with isopropyl
myristate, if needed
Membrane filter
0.45μ porosity
Filter the test
solution
After filtration
remove the filter
Cut the filter
into two halves
28. • Quality Control of Parenteral Products
First halves
(For Bacteria)
Transfer in 100 ml
culture media
(FTM)
Incubate at 30-35
℃ for not less
than 14 days
Observe the
growth in the
media
Second halves
(For Fungi)
Transfer in 100
ml culture media
(SCDM)
Incubate at 20-
25 ℃ for not less
than 14 days
Observe the
growth in the
medium
29. • Quality Control of Parenteral Products
I. Sterility test:
• Method – B (Direct Inoculation Test)
• It involves a direct inoculation of required volume of
a sample in two tests tube
• containing a culture medium that is FTM, SCDM.
• Volume of the preparation under examination is not
more than 10% of the volume of the medium.
• Incubate the inoculated media for not less than 14
days.
30. • Quality Control of Parenteral Products
I. Sterility test:
• INTERPRETATION OF RESULTS
• The following observations are possible:
1. No evidence of growth, the test is passed for
sterility.
2. There is evidence of growth(preserved)
• Re-testing is performed following the initial
procedure for not less than 4 days
• No evidence of growth the test is passed for sterility.
• There is evidence of growth the test is failed for
sterility
31. • Quality Control of Parenteral Products
• CONTENT UNIFORMITY TEST
• 30 sterile units are selected from each batch.
• The weight of 10 individual sterile units is noted
• the content is removed from them and empty
individual sterile unit is weighed accurately again.
• Then net weight is calculated by subtracting empty
sterile unit weight form gross weight.
32. • Quality Control of Parenteral Products
• CONTENT UNIFORMITY TEST
• The dose uniformity is met if the amount of active
ingredient is within the range of 85-115.0% of label
claim.
• If one unit is outside the range of 85-115.0%, and
none of the sterile unit is outside the range of 75-
125.0% or if the relative standard deviation of the
resultant is greater than 6.0% ,or if both condition
prevail, an additional 20 sterile unit should be tested.
33. • Quality Control of Parenteral Products
• CONTENT UNIFORMITY TEST
• The sterile units meet the requirements if not more
than one unit is out side the range of 85-115%, no
unit is outside the range of 75-125.0% and the
calculated relative standard deviation is NMT 7.8%.
34. • Quality Control of Parenteral Products
• Clarity Test
• Performed to ensure that the parenteral products are
free from foreign particles.
• Visual Method
• Coulter Counter Method
• Filtration Method
35. • Quality Control of Parenteral Products
• Clarity Test
Particle Size (μm) Max. no. of particles per
ml
10 50
25 05
50 Nil
36. • Quality Control of Parenteral Products
• Leak Test
• Leaker test for ampoules is intended to detect
incompletely sealed ampoules so that they can be
discarded in order to maintain sterile condition of the
medicines.
• Tip seals are more likely to be incompletely closed
than pull seals.
• Open capillaries or cracks at the point of seal result
in LEAKERS.
37. • Quality Control of Parenteral Products
• Leak Test
• The leaker test is performed by immersing the
ampoules in a dye solution, such as 1% Methylene
blue
• and applying at least 25 inches of vacuum for a
minimum of 15 mins.
• Containers are removed & dye spotted area is
investigated.
38. • Quality Control of Parenteral Products
• Quality control should be a fundamental segment of
parenteral products manufacturing.
• All tests are essential and have its own importance in
parenteral production.
• All of these tests ensure that product meet its quality
which has been judged to satisfactory also.
• Each test is unique and provides detailed
assessment of quality control for parenteral products.
39. 1. Remington, The Science and Practice of Pharmacy,21st edition,Vol-I,p:
812-813,831-833.
2. Kenneth E.Avis,Herbert A.Lieberman and Leon Lachman,“
Pharmaceutical Dosage Forms: Parenteral Medication", Vol.III, 2nd
edition, p :40-41,58-62.
3. Sandeep Nema, John D. Ludwig (eds.)" Pharmaceutical Dosage Forms:
Parenteral Medication", Third Edition, Vol-2,p :122-128, 153-157.